Silverback Therapeutics (SBTX) Competitors $14.40 +0.06 (+0.42%) As of 06/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock SBTX vs. BLTE, HRMY, KNSA, VERA, GMTX, LGND, GLPG, FOLD, AGIO, and CNTAShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), Ligand Pharmaceuticals (LGND), Galapagos (GLPG), Amicus Therapeutics (FOLD), Agios Pharmaceuticals (AGIO), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry. Silverback Therapeutics vs. Its Competitors Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vera Therapeutics Gemini Therapeutics Ligand Pharmaceuticals Galapagos Amicus Therapeutics Agios Pharmaceuticals Centessa Pharmaceuticals Belite Bio (NASDAQ:BLTE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Do analysts recommend BLTE or SBTX? Belite Bio currently has a consensus target price of $96.67, suggesting a potential upside of 61.41%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts plainly believe Belite Bio is more favorable than Silverback Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BLTE or SBTX more profitable? Silverback Therapeutics' return on equity of -29.62% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -31.94% -30.73% Silverback Therapeutics N/A -29.62%-28.20% Which has higher valuation and earnings, BLTE or SBTX? Belite Bio is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$31.63M-$1.36-44.04Silverback TherapeuticsN/AN/A-$89.48M-$2.42-5.95 Which has more risk & volatility, BLTE or SBTX? Belite Bio has a beta of -1.44, meaning that its stock price is 244% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Does the media refer more to BLTE or SBTX? In the previous week, Belite Bio had 9 more articles in the media than Silverback Therapeutics. MarketBeat recorded 10 mentions for Belite Bio and 1 mentions for Silverback Therapeutics. Belite Bio's average media sentiment score of 0.86 beat Silverback Therapeutics' score of 0.00 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silverback Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in BLTE or SBTX? 0.5% of Belite Bio shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in BLTE or SBTX? Belite Bio received 18 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 94.74% of users gave Belite Bio an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote. CompanyUnderperformOutperformBelite BioOutperform Votes3694.74% Underperform Votes25.26%Silverback TherapeuticsOutperform Votes1856.25% Underperform Votes1443.75% SummaryBelite Bio beats Silverback Therapeutics on 9 of the 15 factors compared between the two stocks. Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$519.24M$6.88B$5.59B$8.51BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-5.958.5427.2019.68Price / SalesN/A262.76409.08153.66Price / CashN/A65.8538.3234.64Price / Book1.946.526.974.61Net Income-$89.48M$143.48M$3.23B$248.06M7 Day Performance7.14%0.36%-0.72%-0.82%1 Month Performance8.35%11.11%8.00%3.74%1 Year Performance61.07%2.62%31.77%13.02% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$14.40+0.4%N/A+57.6%$519.24MN/A-5.9583News CoverageBLTEBelite Bio2.6224 of 5 stars$65.02+0.2%$96.67+48.7%+24.3%$2.07BN/A-58.5810Short Interest ↑Analyst RevisionHRMYHarmony Biosciences4.7864 of 5 stars$35.56+3.1%$53.00+49.0%+13.2%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.2721 of 5 stars$27.92+2.0%$38.80+39.0%+46.5%$2.04B$481.17M-199.41220Insider TradeVERAVera Therapeutics2.8778 of 5 stars$31.74+67.5%$65.00+104.8%-40.7%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionGap UpHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+30.9%$2.02BN/A-46.6830High Trading VolumeLGNDLigand Pharmaceuticals4.4601 of 5 stars$101.64-0.5%$146.14+43.8%+42.8%$1.96B$181.49M40.4980News CoveragePositive NewsGLPGGalapagos0.2665 of 5 stars$29.20+1.5%$25.33-13.2%+10.8%$1.92B$288.19M0.001,310FOLDAmicus Therapeutics4.0789 of 5 stars$6.16+1.5%$16.22+163.3%-42.0%$1.90B$543.14M-34.22480AGIOAgios Pharmaceuticals4.0098 of 5 stars$32.63+1.7%$56.00+71.6%-28.1%$1.89B$37.04M2.88390Analyst RevisionCNTACentessa Pharmaceuticals3.7541 of 5 stars$13.41-0.7%$27.89+108.0%+24.1%$1.79B$15M-8.76200Positive News Related Companies and Tools Related Companies BLTE Alternatives HRMY Alternatives KNSA Alternatives VERA Alternatives GMTX Alternatives LGND Alternatives GLPG Alternatives FOLD Alternatives AGIO Alternatives CNTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBTX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
